The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 259-263

  Wong, Michael K K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEMSIROLIMUS;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSFER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FATIGUE; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; SURVIVAL TIME; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 58149118272     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0039-2     Document Type: Review

References (20)

1. Coppin C, Porzsolt F, Awa A, et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, (1):CD001425.
2. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000, 6(Suppl 1):S55-S57.
3. Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 1998, 228:307-319.
4. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995, 22:42-60.
5. Yang JC, Childs R: Immunotherapy for renal cell cancer. J Clin Oncol 2006, 24:5576-5583.
6. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
7. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
8. Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83:797-805.
9. Gitlitz BJ, Hoffman DM, Moldawer N, et al.: Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients. Cancer J 2001, 7:112-120.
10. Sutent (sunitinib) [package insert]. New York, NY: Pfizer Inc.; 2008.
11. Motzer RJ, Rini BI, Bukowski RM, et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
12. Escudier B, Lassau N, Angevin E, et al.: Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007, 13:1801-1809.
13. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
14. Upton MP, Parker RA, Youmans A, et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (1997) 2005, 28:488-495.
15. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
16. Atkins M, Regan M, McDermott D, et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-3721.
17. Schwarzberg T, Regan M, Liu V, et al.: Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy. J Immunother 2007, 30:877-878.
18. Beck KE, Blansfield JA, Tran KQ, et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-2289.
19. Dudley ME, Wunderlich JR, Yang JC, et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
20. Figlin RA: Renal cell carcinoma anW interleukin-2: what are the endpoints? The Cancer Journal 1997, 3(Suppl 1):S68-S69.